Better Cannabis Stock to Buy Right Now: Canopy Growth or Tilray Brands?

Tilray is positioned better than Canopy Growth despite both remaining unprofitable: Q4 net revenue rose 25% YoY to $281.7M, driven by beverage revenue up 60.9% YoY to $105.6M (vs cannabis +5% YoY to $71.5M), while EPS loss narrowed from $13.01 (Q4 2025) to $0.43 (Q4 2026). Canopy’s fiscal Q1 2027 revenue grew 13% YoY to CA$81.2M, but growth is described as largely cannabis-led, with EPS loss improving to CA$0.03 from CA$0.24. Higher net debt at Canopy (about CA$126M net debt vs Tilray roughly $0.7M net debt) limits acquisition flexibility and is framed as a key drag on Canopy’s growth potential.

Analysis

TLRY is starting to look less like a pure cannabis lever and more like a cash-flow composite with multiple shots at re-rating. That matters because investors will usually pay a meaningfully higher multiple for a business that can self-fund and absorb category volatility than for one that still needs external capital to grow. The catch is that gross debt still constrains flexibility, so the equity rerate only sticks if operating cash generation keeps outrunning interest and integration drag over the next 2-4 quarters.

CGC, by contrast, remains trapped in the classic dilution/deleveraging loop: even when operations improve, the balance sheet forces management to optimize for survival rather than optionality. That typically leads to weaker M&A negotiating power, slower product expansion, and a persistent discount to peers because every growth initiative is effectively equity-financed. Second-order, any fragmented asset owners or lenders in the sector will prefer TLRY as the cleaner counterparty, widening the gap in consolidation capacity.

Near term, the main catalyst is the next earnings print and any financing language; the move is likely sentiment-led first, fundamentals-led later. The thesis is falsified if TLRY's margin gains stall or beverage growth normalizes faster than expected, or if CGC manages a credible liability reduction without heavy dilution. Contrarian angle: the market may be underestimating how low-growth beverage assets can cap TLRY's upside if cannabis remains weak; this is probably a relative-value story, not a high-conviction absolute long until cash flow turns durable.

Key Decisions for Investors

• Long TLRY / short CGC as a 1-3 month relative-value pair into the next earnings cycle; thesis is balance-sheet quality and self-funding capacity, with the short leg protected by CGC's dilution overhang.
• Use TLRY only as a tactical long, not a structural compounder; add on confirmation that adjusted EBITDA is translating into free cash flow over the next 1-2 quarters, and cut if that conversion fails.
• Stay short or underweight CGC on any rally driven by restructuring headlines unless net debt is reduced without new equity issuance; a financing event is the main upside-false signal.
• If implied volatility is inexpensive, consider a TLRY call spread rather than outright shares to express upside from a multiple re-rating while limiting exposure to cannabis-sector drawdowns.